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Abstract
Background: The Ras-related GTPase, Rheb, regulates the growth of animal cells. Genetic and
biochemical tests place Rheb upstream of the target of rapamycin (TOR) protein kinase, and
downstream of the tuberous sclerosis complex (TSC1/TSC2) and the insulin-signaling pathway.
TOR activity is regulated by nutritional cues, suggesting that Rheb might either control, or respond
to, nutrient availability.
Results: We show that Rheb and TOR do not promote the import of glucose, bulk amino acids,
or arginine in Drosophila S2 cells, but that both gene products are important regulators of ribosome
biogenesis, protein synthesis, and cell size. S2 cell size, protein synthesis, and glucose import were
largely insensitive to manipulations of insulin signaling components, suggesting that cellular energy
levels and TOR activity can be maintained through insulin/PI3K-independent mechanisms in S2 cell
culture. In vivo in Drosophila larvae, however, we found that insulin signaling can regulate protein
synthesis, and thus may affect TOR activity.
Conclusion: Rheb-TOR signaling controls S2 cell growth by promoting ribosome production and
protein synthesis, but apparently not by direct effects on the import of amino acids or glucose. The
effect of insulin signaling upon TOR activity varies according to cellular type and context.
Background
Rheb (Ras homolog enriched in brain) is a small, highly
conserved guanine triphosphatase (GTPase) that regulates
cell growth in Drosophila and mammals. It has been dem-
onstrated through genetic and biochemical analyses to
function downstream of the tuberous sclerosis complex
(TSC1/TSC2) and upstream of the conserved protein
kinase, target of rapamycin (TOR; [1-3]), which regulates
many processes important for cell growth including pro-
tein synthesis, ribosome biogenesis, autophagy, and (in
yeast) amino acid import [4-10]. TSC2, a known tumor
suppressor, acts as a GTPase-activating protein (GAP) for
Rheb [11-18], and thus inhibits Rheb activity via direct
molecular interaction. It remains less clear how Rheb acti-
vates TOR, or how TOR activity drives cell growth. In a
previous publication [2], we discussed two possible mech-
anisms via which Rheb might mediate its downstream
effects. The first possibility is that Rheb activates TOR indi-
rectly by promoting nutrient import at the plasma mem-
brane, and thereby increases intracellular nutrient and/or
energy pools. As TOR activity can be regulated by both
amino acid levels and cellular energy levels as provided by
glucose [14,19,20], this might explain the dependence of
TOR activity upon Rheb. This possibility is consistent with
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the ability of Rheb to promote cell growth in amino acid-
starved Drosophila larvae; the ability of other related small
GTPases, such as the Rab GTPases, to promote endocyto-
sis and glucose import [21,22]; the presumed localization
of Rheb at the plasma membrane [23]; and the ability of
insulin signaling, which has been reported to modulate
Rheb-GTP loading [12], to promote glucose import in
many cell types [24]. It is also consistent with studies from
yeast showing that TOR regulates amino acid permeases
[25]. Alternatively, Rheb might activate TOR through
direct molecular interactions [26-29]. This simpler possi-
bility is more consistent with the inability of cells with
mutations in the TOR gene to grow even when Rheb is
overexpressed, and with the ability of overexpressed Rheb
to activate TOR targets in amino acid-deprived cells [2]. In
this report, we evaluate these two possible mechanisms,
and present data consistent with the second possibility.
We also delve into the relationship between insulin sign-
aling and TOR, and conclude that the ability of insulin
signaling to regulate TOR is dependent on cell type, and
may vary within a given cell type as nutritional conditions
change.
Results
S2 cells deficient in Rheb or TOR are reduced in size
To test the aforementioned hypotheses,Drosophila Schnei-
der line 2 (S2) cells were treated with double-stranded
RNA (dsRNA, RNAi) to deplete Rheb, TSC2, or other rele-
vant proteins that function in the insulin and TOR signal-
transduction pathways. To confirm dsRNA knockdown of
the targeted mRNAs, quantitative real time reverse tran-
scription (RT) PCR or Northern analyses were performed
(Additional file 1). Using a Beckman Coulter Counter to
measure cell volumes, we noted that S2 cells subjected to
72 hours of dsRheb- or dsTOR-treatment were smaller
than control cells (Figure 1A). This is consistent with pre-
viously published results from S2 cells and other systems,
and is also seen in vivo in Drosophila rheb, TOR, or s6k (a
TOR target) gene mutants [1,2,30,31].
General amino acid import is not impaired in cells 
deficient in Rheb or TOR
To test the hypothesis that Rheb directly controls the cel-
lular import of amino acids, we developed a simple
amino-acid import assay. At 72 hours after treatment with
dsRNA, cells were transferred to an isosmotic salt solution
containing a mix of 15 tritiated amino acids at 22°C. At
time-points following this, the cells were washed and
lysed, and the amount of 3H in the lysates was determined
using a scintillation counter. Time courses of cellular
uptake of amino acids revealed that treatment of S2 cells
with dsRNA directed against Rheb or TOR consistently
caused a slight increase in amino-acid import relative to
control cells, which were treated with dsRNA against GFP,
when the data were normalized per cell volume (Fig 1B)
or per total cellular protein (not shown). Similar assays
were performed on cells treated for 30 min with rapamy-
cin, an inhibitor of TOR, or LY294002, an inhibitor of
PI3K as well as TOR. These short treatments did not
change cell size, and detected no significant deficits in
amino-acid import. Longer exposures to rapamycin (5–50
hrs) also had no detectable effect on amino-acid uptake.
As a control for the biological relevance of the assay, we
performed several import assays on ice at 0°C. This
blocked 3H-amino acid uptake nearly completely, and the
effect was rapidly reversed by restoring the cells to 22°C
(data not shown). Overall, these results indicate that the
activity of Rheb and TOR is not an important regulator of
bulk amino-acid import. Hence, we suggest that the pro-
motion of general amino-acid import is not likely to be a
critical function of either Rheb or TOR in regulating S2
cell growth.
Arginine import is increased, not reduced, in cells deficient 
in Rheb or TOR
Two recent reports suggest that TOR might control cell
growth by specifically regulating the import of basic
amino acids via a cationic amino-acid permease encoded
by the slimfast (slif) gene [32,33]. These studies show that
slif is required for normal rates of organ growth in flies,
that its localization to the plasma membrane of adipose
cells in the fat body is controlled by TOR activity, and that
it is a limiting regulator of arginine import in S2 cells. The
role of TOR in regulating arginine import, however, was
not tested directly. To investigate the possibility that TOR
regulates cell growth by specifically controlling the import
of basic amino acids, we used RNAi to deplete Rheb or
TOR and then measured the uptake of 3H-arginine in S2
cells. Experiments performed in triplicate indicated that
rates of 3H-Arg uptake were not reduced, but instead
showed a small but reproducible increase, in cells
depleted of Rheb or TOR (Figure 1C). These data are
inconsistent with models in which the growth effects of
TOR are mediated via Slif and the import of basic amino
acids, but they concur with the observation that arginine
import is increased in yeast mutant for Rheb [34]. The
basis of this effect is not clear; Rheb/TOR signaling might
negatively regulate arginine importers, or the effect may
be an indirect, compensatory response to reductions in
another TOR-regulated process, such as protein synthesis
(see below).
Glucose import is not impaired in cells deficient in Rheb or 
TOR
Genetic epistasis tests and biochemical evidence place
Drosophila Rheb downstream of the insulin receptor (InR),
phosphoinositide-3-kinase (PI3K) and the oncogenic pro-
tein kinase, Akt (also known as PKB), in the insulin-sign-
aling cascade [1-3,12,18,30]. In mammals, insulin
signaling functions to enhance glucose import in skeletalBMC Biology 2007, 5:10 http://www.biomedcentral.com/1741-7007/5/10
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Nutrient uptake in Drosophila S2 cells Figure 1
Nutrient uptake in Drosophila S2 cells. Representative data obtained from nutrient import experiments performed in 
triplicate following 72-hour treatments using dsRNA (RNAi) directed against Rheb, TOR, or GFP (control) to deplete the tar-
get transcript. (A) Histogram generated (Coulter Counter Z2 software) demonstrating that dsRheb-treated and dsTOR-
treated cells are smaller than dsGFP-treated control cells.(B) Bulk amino-acid import normalized to cell number and volume 
shows that dsRheb-treated and dsTOR-treated cells are not deficient for general amino-acid import. (C) Arginine import nor-
malized to cell number and volume shows that dsRheb-treated and dsTOR-treated cells have increased levels of arginine 
import. (D) Cellular 2-deoxyglucose import, when normalized to cell number, is significantly reduced in cells treated with dsR-
heb or dsTOR. When 2DG import is normalized using mean cellular volume (E), or total cellular protein content (F), 2DG 
import in dsRheb-treated or dsTOR-treated cells is comparable with controls. G) Effects of insulin signaling on 2DG import. 
Data represent percentage of control 2DG import at 25 (insulin experiments) or 35 minutes after 2DG addition. For the first 
six bars, growing subconfluent cells were deprived of serum for the indicated periods, and then stimulated with 10 μg/mL 
bovine insulin for 5 minutes prior to addition of 2DG. Wortmannin (Wort), LY294002 (LY), and 1L-6-Hydroxymethyl-chiro-
inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate (AKT-Inh) were added to cells at the indicated doses 30 minutes before 
addition of 2DG, in the presence of serum. dsRNA directed against Akt (AKTi), PI3K (PI3Ki), or Glut1 (Glut1i) was applied 72 
h beforre 2DG addition, also in the presence of serum. Error bars represent standard deviations of duplicate assays.BMC Biology 2007, 5:10 http://www.biomedcentral.com/1741-7007/5/10
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muscle and adipose tissue [24,35]. Moreover, the small
GTPases Rab11 and Rab4, as well as a Rab-GAP, have been
implicated in mediating translocation of the glucose
importer GLUT4 to the plasma membrane upon insulin
stimulation [21,22]. The influence of Rheb on glucose
uptake was therefore tested. S2 cells were treated with
dsRNA directed against Rheb for 72 hours, after which
time rates of cellular import of tritiated 2-deoxyglucose
(2DG) were measured. 2DG is a glucose analog that enters
the cell and is phosphorylated to 2-DG-6-phosphate. It is
not metabolized further and hence accumulates intracel-
lularly [36]. dsRheb-treated S2 cells had a consistent, sig-
nificant reduction in cellular 2DG import compared with
dsGFP-treated control cells (Figure 1D). Inhibition of
TOR with either dsRNA or 16-hour treatment with
rapamycin yielded similar results. However, when these
2DG import data were corrected for differences in cell size
or protein content, no effects of either loss of TOR or Rheb
were apparent (Figures 1E, F). Moreover, a time-course of
inhibition of TOR by rapamycin demonstrated that a defi-
ciency in 2DG import was not observed until there was
also an observable change in cell size (data not shown).
Therefore, the decreased 2DG uptake can be attributed to
the reduction in cell size, provided that we assume that
the number of glucose importers per cell drops propor-
tionally to the loss of surface area. These findings weigh
against models in which Rheb activates TOR by stimulat-
ing glucose import. Moreover, they imply that the
decreased size of cells lacking Rheb or TOR cannot be
attributed to decreased glucose or amino-acid import.
Insulin signaling has only minor effects on glucose import
Insulin signaling is an important regulator of glucose
import in some mammalian cell types [24,35], and in vivo
studies suggest that this function is conserved in Dro-
sophila [37,38]. It has been proposed that insulin signaling
might promote TOR activity by increasing glucose import
and thereby supporting ATP pools [5,39]. To assess this
possibility in Drosophila, we measured rates of glucose
import in S2 cells stimulated with 10 μg/mL bovine insu-
lin after various periods of serum starvation. As shown in
Figure 1G, insulin markedly stimulated glucose import
only in cells that had been starved of serum (and the insu-
lin within it) for short periods of time (2–6 hours). Insu-
lin stimulation of S2 cells that had not been serum-
starved, or that had been serum-starved for 24 hours or
more, had no significant effect on rates of glucose import.
This indicates that S2 cells are capable of importing glu-
cose independently of their insulin-signaling activity. We
also assessed, in serum-stimulated cells, the effects of
inhibiting insulin-signaling components with inhibitors
or RNAi. Short-term inhibition of insulin signaling was
achieved with the PI3K inhibitor wortmannin (see
[40,41]) or an AKT inhibitor (1L-6-Hydroxymethyl-chiro-
inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate; Cal-
biochem), and long-term inhibition of insulin signaling
was achieved using dsRNA directed against PI3K or Akt.
None of these treatments had major effects on rates of glu-
cose import (Figure 1G). We also used RNAi to assess the
potential role of Glut1, the Drosophila glucose transporter
most homologous to mammalian Glut4, which mediates
insulin-dependent glucose import in fat and muscle
[24,35]. Although the Glut1 gene is essential for viability
in vivo in Drosophila, RNAi-mediated depletion of Glut1 in
S2 cells had no detectable effect on glucose import (Figure
1G). All these results indicate that insulin signaling via
PI3K and Akt plays only a minor, conditional role in con-
trolling glucose import into S2 cells.
These results are in marked contrast to the strong dose-
dependent inhibition of 2DG import seen following a
short (30 minute) pre-treatment with the kinase inhibitor
LY294002. This drug inhibits PI3K relatively specifically at
low concentrations, but inhibits TOR and other kinases at
higher concentrations. LY294002 blocked glucose import
nearly completely at either 20 μM or 100 μM (Figure 1G).
This indicates that glucose import is in fact regulated in S2
cells, but by an LY294002 target other than PI3K or TOR.
To further assess the role of glucose in controlling cell size,
we used dsRNA to deplete adenosine monophosphate
activated protein kinase (AMPK), a kinase that is activated
by AMP when cellular energy levels are low, and which
suppresses TOR activity by activating TSC2 [14,42,43].
Depletion of AMPK by RNAi caused an increase in cell size
(mean volume for AMPKi = 681fL; GFPi = 636fL, p  =
0.0011, n = 4; Figure 2A), providing corroborating evi-
dence for a link between cellular energy levels and cell size
control that could be mediated by TOR.
Rheb and TOR are required for normal rates of protein 
synthesis
Having determined that Rheb and TOR do not drive S2
cell growth by promoting nutrient import, we considered
the established role for TOR and its downstream targets in
the control of protein synthesis. A translation assay was
developed to test whether decreased translation could
account for the small size of dsRheb- and dsTOR-treated
cells. S2 cells were treated with dsRNA for 72 hours, after
which the incorporation of radiolabeled amino acids into
protein, relative to total protein, was measured over a 3-
hour period. To validate this assay, cells were pretreated
for 2 hours with the general protein synthesis inhibitor
cycloheximide (100 μg/mL). This caused a reduction in
the incorporation of amino acids to approximately 7% of
control values. Cells treated with dsRNA directed against
Rheb or TOR had a significantly reduced proportion of
protein labeled compared to dsGFP-treated controls
(approximately 60% of controls) (Figure 2A).BMC Biology 2007, 5:10 http://www.biomedcentral.com/1741-7007/5/10
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Regulation of translation and cell size by the TOR network Figure 2
Regulation of translation and cell size by the TOR network. (A) Protein synthesis and mean cell volumes are plotted, as per-
centage of controls. The white number at the base of each pair of bars indicates the number of experiments performed and 
analyzed for each RNAi treatment. (B) Inhibition of TOR blocks protein synthesis before affecting cell size. Cells were pre-
treated with rapamycin or DMSO (control) for 20 minutes prior to addition of 3H-amino acids for a 3-hour translation assay. 
Translation was markedly reduced in rapamycin-treated cells, while cell size remained normal. (C) Co-treatment with dsATG5 
or dsATG7 was unable to rescue cell size in dsRheb-treated or dsTOR-treated cells. Cells were pretreated 72 hours with 
dsATG5, dsATG7, or dsGFP as control to deplete cells of ATG proteins, then the cells were treated with both listed dsRNAs 
for an additional 72-hour period to determine if loss of autophagy could rescue the cell size. Error bars represent the standard 
deviations.BMC Biology 2007, 5:10 http://www.biomedcentral.com/1741-7007/5/10
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In mammalian and Drosophila cells, TOR has been found
in two separate complexes; a Rictor-TOR complex, and a
Raptor-TOR complex [44-46]. The Raptor-TOR complex
appears to be the primary functional complex for serum-
dependent or rapamycin-dependent and cell-growth func-
tions of TOR [44]. Accordingly, Raptor was tested for roles
in protein synthesis and cell size control. dsRaptor treat-
ment phenocopied dsRheb and dsTOR treatments, in that
both cell size and protein synthesis were significantly
reduced (Figure 2A). We also found that protein synthesis
was markedly reduced, but cell size was unchanged, after
a short (20 minute) pre-treatment with 10 ng/mL rapamy-
cin (Figure 2B). Together, these data suggest that a pri-
mary effect of Rheb, TOR, and Raptor is to control
translation rates.
Overexpressed Rheb drives protein synthesis in vivo
To ascertain the effects of increasing Rheb activity on pro-
tein synthesis, we turned to an in vivo assay in Drosophila
larvae. The hsFLP/Gal4 system [47] was used to induce
high levels of Rheb expression in most cells of third instar,
pre-wandering larvae. The larvae were inverted 20 hours
after gene induction, and then incubated for 1 hour in
Ringer's saline solution containing 3H-amino acids. Pro-
tein samples from larval lysates were then prepared and
processed as in the S2 cell assay used above. Fed larvae
overexpressing Rheb showed an increase in protein syn-
thesis of 140–180% relative to controls (Figure 3A). Pre-
vious studies have shown that larvae starved of dietary
protein have reduced levels of insulin and TOR signaling
activity [33,48,49], and that overexpressed Rheb can drive
cell growth in such larvae, which are normally growth-
arrested [2]. Thus, we tested whether Rheb was also capa-
ble of stimulating protein synthesis in protein-starved lar-
vae. Larvae starved of dietary protein for 32 hours prior to
heat-shock induction of Rheb had more than twice the
translation rate of controls starved in parallel (Figure 3B).
These data indicate that Rheb is a potent regulator of pro-
tein synthesis in Drosophila, and are consistent with the
view that Rheb and TOR are used to modulate rates of pro-
tein synthesis in response to changes in the levels of die-
tary protein.
Insulin signaling also regulates translation in larvae
Given the abundance of data demonstrating a relation-
ship between TOR activity and insulin signaling, we were
surprised to find that suppression of PI3K signaling in S2
cells had no significant effect on cell size or translation
(Figure 2A). To further investigate the relationship of
insulin signaling to TOR, insulin-signaling components
were overexpressed in whole larvae using the hsFLP/Gal4
system. Larvae overexpressing Dp110, the catalytic subu-
nit of PI3K, had a significantly enhanced level of transla-
tion relative to controls, though the effect was less
profound than that of overexpressed Rheb. Consistently,
larvae overexpressing PTEN, a negative regulator of PI3K,
had lower levels of protein synthesis than controls (Figure
3C). This result corroborates previous findings that sug-
gest a link between insulin signaling and activation of
Rheb-TOR signaling in vivo.
S6K and 4EBP cannot account for the translational effects 
of TOR
The ribosomal protein S6 kinase (S6K) and eukaryotic ini-
tiation factor 4E binding protein (4EBP) are both targets
of TOR in mammals and flies [50] and are well-known
regulators of protein synthesis. Flies and mice mutant for
s6k have reduced body size due to a reduction in cell size,
although they have a normal number of total body cells
[30,51]. Treatment of S2 cells with dsRNA directed against
S6K also reduced cell size and protein synthetic rate, but
not as drastically as did dsRheb or dsTOR treatment (Fig-
ure 2A). This is consistent with our previous finding that
overexpressed Rheb can drive cell growth in s6k mutant
animals [2], and indicates that S6K is not the sole media-
tor of cell size and protein synthesis downstream of TOR.
4EBP is a well-characterized TOR target that functions by
sequestering the mRNA cap-binding protein, eukaryotic
initiation factor 4E (eIF4E). Phosphorylation of 4EBP by
TOR releases eIF4E and allows it to bind the eIF4G scaf-
fold protein, which, in a complex with other components,
binds the 5' cap region of mRNAs to initiate translation.
Ectopic expression of an active form of Drosophila 4EBP
(known as Thor), a negative regulator of translation,
results in reduced wing size due to reductions in cell size
and cell number [52]. Given these observations, we
attempted to rescue the cell size and translation defects
observed in dsTOR-treated S2 cells by codepleting 4EBP
with dsRNA. Treatment with ds4EBP alone had no detect-
able effect on cell size or protein synthesis rates. Moreo-
ver, in co-depletion experiments, ds4EBP did not lessen
the reductions in cell size and translation caused by
dsTOR or dsRheb treatment (data not shown). Therefore,
negative regulation of 4EBP by Rheb and TOR appears not
to be an important mode of growth control in S2 cells. We
did find, however, that dsRNA directed against Drosophila
eIF4E or eIF4G resulted in small cells with greatly reduced
translation (Figure 2A). Considering the similarity to the
dsTOR and dsRheb phenotypes, this is consistent with the
proposal that TOR is required for proper eIF4G function
and translation initiation [53].
Small cell size is a TOR pathway-specific phenotype
Because inhibition of any component of the protein syn-
thesis machinery could be reasoned to have these same
phenotypic consequences, two ribosomal proteins were
also tested. Treatment of cells with dsRNA targeting ribos-
omal proteins S3 or S13 did not cause a demonstrable
alteration in cell size, despite severely reducing rates ofBMC Biology 2007, 5:10 http://www.biomedcentral.com/1741-7007/5/10
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Rheb, PI3K, and PTEN modulate translation in Drosophila larvae Figure 3
Rheb, PI3K, and PTEN modulate translation in Drosophila larvae. Representative experiments in which the indicated gene was 
overexpressed in whole third instar, pre-wandering larvae using the hsFLP/Gal4-UAS system of induction 20 hrs prior to the 
translation assay. Gray bars represent means as a percentage of the control mean. (A) Rheb overexpression in fed larvae 
drives protein synthesis. (B) Overexpressed Rheb promotes protein synthesis in larvae starved of protein for 32 hrs prior to, 
and during, induction. (C) Dp110, the catalytic subunit of Drosophila PI3K, also promotes translation, whereas PTEN, a negative 
regulator in the insulin/PI3K pathway, inhibits translation. Error bars indicate the standard deviations of the mean.BMC Biology 2007, 5:10 http://www.biomedcentral.com/1741-7007/5/10
Page 8 of 15
(page number not for citation purposes)
translation (Figure 2A) and cell division (data not
shown). Although this failure to affect cell size could be
due to differences in the kinetics of target depletion by dif-
ferent types of RNAi, we believe it is meaningful because,
whereas the TOR pathway suppression invariably reduces
cell size, reducing protein synthesis by other means rarely
does so. For instance, heterozygosity for ribosomal gene
mutations (Minutes) slows growth dramatically in vivo, yet
does not reduce cell size, and sometimes even increases it
(our unpublished observations). Moreover, whole-
genome screening using RNAi in S2 cells has failed to
detect ribosomal protein genes as regulators of cell size
[54], whereas TOR pathway components and targets are
readily detected [31,54]. Hence, we surmise that smaller
cell size is not a necessary consequence of reduced protein
synthesis, and that other targets in addition to S6K and
4EBP mediate the effects of TOR on cell size. A recent
report duplicating many of these results corroborates
these conclusions [31].
Autophagy
Recent studies have demonstrated that TOR activity sup-
presses autophagy, a catabolic process whereby starved
cells engulf and break down their cytoplasm and
organelles, which occurs in flies, yeast, and mammalian
cells [9,55,56]. We therefore considered the possibility
that depletion of TOR in S2 cells may induce autophagy,
and that this might account for the reduced cell size seen
in dsTOR-treated or dsRheb-treated cells. To test this
hypothesis, two proteins required for autophagy, ATG5
and ATG7 [9], were targeted for depletion using RNAi,
either alone or in combination with dsTOR or dsRheb
treatment. In some cases, we pre-depleted the cells of
ATG5 or ATG7 by applying the RNAi against these targets
3days prior to RNAi directed against Rheb or TOR. In all
cases, we found that depletion of these ATG mRNAs had
no significant effect on cell size, and did not rescue the
reduction in cell size caused by depletion of either Rheb
or TOR (Figure 2C). These results support the hypothesis
that the reduction in cell size is primarily due to the reduc-
tion in protein synthesis, and not to an increase in protein
breakdown via autophagy.
TOR and Rheb promote ribosome biogenesis
Given that S6K, 4EBP, and autophagy appeared to be
insufficient to account for the effects of Rheb and TOR on
protein synthesis and cell size, we sought other explana-
tions. Because TOR signaling regulates ribosome biogen-
esis in both yeast and mammalian cells [7,8], the effect of
loss of either Rheb or TOR on ribosome synthesis in S2
cells was examined. S2 cells treated with dsRheb and
dsTOR showed reduced levels of rRNA synthesis as meas-
ured by Northern blotting using an internal transcribed
spacer probe that hybridizes to the 45S pre-rRNA (Figure
4C). Similarly, rapamycin-treated S2 cells also had
reduced levels of pre-rRNA (data not shown). Levels of
total (mature) rRNA were also reduced in both dsRheb-
treated and dsTOR-treated cells, indicating that these cells
have fewer ribosomes (Figure 4C). Consistent with this
result, S2 cells treated with rapamycin had smaller nucle-
oli than controls (Figures 4A, B). In contrast, depletion of
either PI3K or Akt had no detectable effect on either pre-
rRNA or total rRNA levels in S2 cells (data not shown).
This is consistent with our finding that neither dsPI3K nor
dsAkt treatment significantly affected either translation
nor cell size in our S2 cell assays. Thus, Rheb and TOR reg-
ulate ribosome biogenesis in Drosophila S2 cells, and do so
independently of PI3K and Akt.
Discussion
We initiated this study to determine which of the down-
stream outputs of the insulin-TOR signaling network are
the most important effectors of cell growth, and also to
probe the functional relationships between Rheb, TOR,
and the insulin signaling system. The literature reports
many growth-associated processes as being dependent
upon insulin signaling and/or TOR function [10,25].
These include translational initiation [6,57], ribosome
biogenesis [7,8], glucose import and glycolysis [5,24],
amino-acid import [5], autophagy [55], transcriptional
programs relevant to metabolism and stress response
[38,58-60], and control of the actin cytoskeleton [61].
While some of these processes are affected directly by Akt-
dependent or TOR-dependent phosphorylation of known
substrates, others probably represent indirect effects of
general changes in metabolism caused by altering insulin
or TOR signaling. As the relative importance of different
growth processes will vary according to cell type and
organism, comparisons of data from different experimen-
tal systems are often inconclusive. Hence we surveyed a
number of growth-related processes in a single cell type,
the  Drosophila  S2 cell. These embryo-derived cells are
thought to be related to phagocytic haematocytes. They
are relatively well characterized and are highly sensitive to
RNAi-mediated suppression of gene function. TOR activ-
ity in S2 cells, as assayed by S6K or 4EBP phosphorylation,
has been demonstrated to be responsive to insulin signal-
ing and to glucose and amino acid levels, at least in short-
term assays [2,40,41,49,50].
First, we noted that depletion of Rheb, TOR, or Raptor, or
treatment of cells with rapamycin, caused very similar
effects on all the growth-related processes that we assayed.
This is in agreement with the prevailing view in which
these three factors function together as a regulatory mod-
ule [26,27,44,62]. Second, we found that the depletion of
Rheb or TOR decreased rates of bulk protein synthesis and
ribosome production without reducing rates of bulk
amino acid import, arginine import, or glucose import.
This implies that Rheb does not regulate TOR by control-BMC Biology 2007, 5:10 http://www.biomedcentral.com/1741-7007/5/10
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Rheb and TOR regulate ribosome biogenesis Figure 4
Rheb and TOR regulate ribosome biogenesis. (A, B) Nucleoli visualized by anti-fibrillarin staining (green) [84], in S2 cells 
treated with (A) DMSO or (B) rapamycin for 16h. DNA was visualized using Hoechst 33258 (blue). (C) Northern blots of 
RNA from S2 cells treated for 72h with the indicated dsRNA. A probe for an internal transcribed spacer (ITS) region of the 
rDNA was used to detect pre-rRNA. Total rRNA was detected with ethidium bromide. A probe for dMyc transcript was used 
as a loading control. (D) Quantification, using ImageJ software, of pre-rRNA and total rRNA, relative to dMyc mRNA, from 
the samples shown in (C).BMC Biology 2007, 5:10 http://www.biomedcentral.com/1741-7007/5/10
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ling nutrient availability (as we suggested in an earlier
publication [2]) but is consistent with the proposal that
Rheb activates TOR by direct physical interaction [26-29].
Our results also imply that Rheb/TOR signaling does not
control cell growth via direct effects on nutrient import.
One caveat to this interpretation is that the reduction in
growth rate resulting from depletion of Rheb or TOR is
small, amounting to a ~50% reduction in the mass of an
S2 cell culture over 72 hrs. Even considering that most of
this reduction in growth is sustained during the last 24 hrs
of culture, after the RNAi becomes fully penetrant, it is
doubtful that we could detect the small deficits in nutrient
import (< 5%) required to explain this mass deficit using
assays lasting at most 1 hr. Notwithstanding this caveat,
the effects of TOR inhibition on protein synthesis were
large and rapid and preceded decreases in cell size (Figure
2B), suggesting that the loss of cell mass after TOR inhibi-
tion is likely to be due to the reduction in protein synthe-
sis.
Other factors could of course contribute to the effects of
Rheb/TOR signaling on cell size and growth rate. These
include changes in the relative rates of nutrient storage,
utilization for energy, export, and of macromolecule deg-
radation and cell death. The balance of all these processes
determines the steady-state cell size and growth rate of the
culture as a whole. Although we did not assay all of these
processes after suppressing TOR function, we did attempt
to rescue the TOR-dependent reduction in cell size by
inhibiting autophagy, using RNAi directed at two genes
required for that process. No rescue was achieved, suggest-
ing that the loss of S2 cell mass that occurs after Rheb or
TOR inhibition is not due to increased autophagy. Studies
performed in vivo in Drosophila larvae, using a similar strat-
egy, have arrived at the same conclusion [9].
Although we favor the idea that the cell size reduction that
occurs when TOR activity is suppressed results from
reduced protein synthesis, we note that these cell-size
effects were specific to TOR pathway components, and
were not reproduced using RNAi directed against ribos-
omal proteins, or by the translation inhibitor cyclohex-
imide (Figure 2). This specificity is also observed in vivo,
where mutations in ribosomal protein genes (Minutes)
reduce growth rates, but do not reduce cell size. The origin
of the TOR-specific cell size decrease remains a mystery,
but may lie in the differential effects of TOR on the trans-
lation of specific classes of mRNAs, such as cap-depend-
ent, internal ribosome entry site-dependent, and 5'
terminal oligo-pyrimidine-containing mRNAs. By having
relatively severe effects on the translation of mRNAs
encoding products involved in processes such as protein
turnover, nutrient storage, or cell cycle progression, TOR
might alter the balance between rates of cell growth and
division, and thus affect cell size. Analysis of the effects of
TOR on the translation of the entire spectrum of specific
proteins may clarify how it controls cell size. As noted
above, it is also possible that TOR-mediated regulation of
growth-related processes unrelated to protein synthesis,
such as transcription or nutrient utilization, account for
much of TOR's effect on cell size (see, for instance Guertin
et al [31]).
TOR has several well-characterized targets that modulate
protein synthesis, notably the ribosomal protein S6K and
the initiation factor 4EBP (reviewed by Hay and Sonen-
berg [6] and Wullschleger et al[10]). Our data indicate
that S6K and the 4EBP target eIF4E, which can be activated
by TOR, could account for a portion of the effect of TOR
on protein synthesis and cell size in S2 cells, although not
the total effect (Figure 2A). This is consistent with in vivo
studies in Drosophila and mice showing that S6K, in con-
trast to Rheb and TOR, is a non-essential gene product
that has relatively mild effects on cell growth in normal
culture conditions [30,51], and that 4EBP is dispensable
[52]. Thus, many results underline the importance of
identifying factors other than S6K and 4EBP, through
which Rheb/TOR signaling regulates protein synthesis.
The literature suggests that TOR regulates protein synthe-
sis through multiple targets that work both directly, by
controlling rates of translation initiation and elongation,
and indirectly, by controlling ribosome supply. TOR may
control ribosome supply in part via TIF-IA and UBF, two
regulators of RNA polymerase I activity [63,64]. In yeast,
TOR also regulates the expression of ribosomal protein
gene expression via protein kinase A (PKA) and the fork-
head-like transcription factor, FHL1 [7,65]. However, his
mechanism is not supported by gene expression profiling
experiments in S2 cells [31], which show that TOR regu-
lates many genes involved in ribosome assembly, but
does not affect the expression of mRNAs encoding the
ribosomal proteins. Interestingly, RNAi-mediated sup-
pression of 54 TOR-regulated genes (65% of the TOR tar-
gets identified) reduced cell size, suggesting that the total
effect of TOR on cell size is the sum of many small tran-
scriptional effects. Finally, we note that experiments with
rapamycin show that TOR has immediate effects on pro-
tein synthesis that are unlikely to result from reduced
ribosome numbers. In addition to S6K and 4EBP, these
rapid effects could result from the effects of TOR on the
elongation factor eEF2 [66] or on the translation initia-
tion factors eIF2α [67] and eIF4G [53].
Another issue addressed here is the relationship of insulin
signaling to TOR activity. Many studies have implicated
insulin signaling as an important regulator of TOR activity
[12,41,50,68-70], and two general mechanisms have been
proposed to explain this control. The first is a direct mech-
anism in which TSC2 is inactivated by phosphorylation
by Akt [71-74]. The second is an indirect mechanism inBMC Biology 2007, 5:10 http://www.biomedcentral.com/1741-7007/5/10
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which insulin signaling promotes glucose import and
raises the ATP/AMP ratio, which suppresses AMPK and
thereby inactivates TSC2 [5,14,39,42,43]. While both are
attractive mechanisms of control, our data suggests that
they play relatively minor roles in controlling TOR in S2
cell culture. We found that inhibition of PI3K or Akt with
either RNAi or chemical inhibitors had much smaller
effects on cell size and protein synthesis than did inhibi-
tion of TOR, Rheb, or Raptor (Figure 2). Three independ-
ent studies have corroborated our observations regarding
cell size [31,54,75]. Furthermore, we found that insulin
and some of its downstream effectors are not required for
glucose import in S2 cells, and that insulin significantly
stimulated glucose import only when the cells had been
serum-starved for a short time (Figure 1G). Consistent
with these observations, we and others have found that S2
cells can grow and proliferate in serum-free media with-
out insulin [76]. Along with other studies [49,50,69,74],
these results indicate that insulin signaling via PI3K and
Akt does not act as an important regulator of TOR activity
in all cellular contexts. This is likely to be the case in S2
cells, at least when they are grown in nutrient-rich media.
TOR activity has also been found to be insulin-independ-
ent in mammalian CHO and HEK293 cells [77], and so
this relationship may not be so unusual.
Considering the limited affects of insulin, PI3K, and Akt
on S2 cell growth, the rapid TOR-dependent phosphoryla-
tion of S6K and 4EBP that occurs when these cells are
stimulated with insulin [41,50,69] seems paradoxical.
Although we cannot explain this apparent discrepancy, we
suggest that insulin stimulation may have transient effects
(e.g. S6K phosphorylation) that do not correlate well with
long-term outcomes such as changes in cell size or ribos-
ome production. It may also be that the "basal" insulin-
independent level of TOR activity in S2 cells grown in
nutrient-rich media is sufficient to maintain high rates of
protein synthesis and a large cell size. Further activation of
TOR in this context, by insulin stimulation or loss of
TSC2, might increase S6K and 4EBP phosphorylation
without appreciably upregulating actual cell growth. This
explanation seems consistent with previously published
data, which documented insulin-dependent phosphoryla-
tion of TOR targets in S2 cells cultured under the same
conditions we used, but did not assay the effects of insulin
signaling on cell growth. Our observation that depletion
of TSC2 in S2 cells did not detectably increase protein syn-
thesis rates, and caused only a modest increase in cell size
(Figure 2), is also consistent with this explanation. In
other cellular contexts, such as in feeding larvae or adult
flies, insulin signaling does have profound effects on glu-
cose metabolism [37,38], cell growth, and size [48,78-
81]. Thus, we believe that insulin signaling is a major reg-
ulator of both cellular energy levels and TOR activity in
many contexts in vivo. Indeed, we were able to document
a significant effect of insulin signaling on protein synthe-
sis in living Drosophila larvae (Figure 3C). Even in vivo
however, recent evidence suggests that the requirement
for insulin signaling may vary according to tissue type
[37].
Conclusion
In summary, our results argue against a significant or
direct role for Rheb-TOR signaling in promoting nutrient
import, but corroborate the established role of TOR as an
important regulator of protein synthesis and ribosome
production. Our findings also highlight the variable rela-
tionship between insulin signaling and TOR activity, and
cast doubt upon the relevance of insulin as a regulator of
TOR in Drosophila S2 cells.
Methods
dsRNA synthesis
cDNAs encoding the proteins of interest were obtained
and amplified by PCR using composite primers (details
available on request), of which the 3' 20 base pairs were
gene-specific and the 5' ends had a T7 RNA polymerase
binding site. The double-stranded PCR products, which
contained a portion of the coding sequence for the pro-
tein to be depleted flanked by T7 polymerase binding
sites, were purified using a commercial kit (QIAquick Gel
Extraction kit; Qiagen, Valencia CA, USA) and then used
as template for RNA synthesis using a T7 RNA polymerase
(Megascript T7 kit; Ambion, Austin TX, USA). RNA was
precipitated by standard procedures using sodium acetate
and ethanol for precipitation. To anneal complementary
transcribed products, the RNA was heated to 65°C for 30
minutes and slowly cooled to room temperature before
being quantified by UV spectrophotometry and diluted to
a working concentration of 1 μg/μL. Template DNA for
T7-cDNA synthesis was obtained from the DGC clone col-
lection or by reverse transcription (SuperScript II; Invitro-
gen, Carlsbad, CA, USA) and PCR amplification of an S2
RNA product using sequence-specific primers. In the latter
cases, the T7-cDNA was sequenced to verify that the
expected product was obtained. The Drosophila genome
encodes seven highly related eIF4E genes [82], and the
dsRNA we used is predicted to target the four most abun-
dantly expressed isoforms.
dsRNA interference
Interference was performed as described previously [83].
Briefly, S2 cells from an actively growing cell culture were
collected by centrifugation and resuspended in serum-free
media (SFM, Hy-Q, Hy-Clone, Logan UT, USA) at a den-
sity of 1 × 106 cells/mL in one well of a six-well plate, then
20 μg dsRNA was added to the cells. After 1 hour of incu-
bation in the SFM, 2 mL Schneider's Drosophila medium
containing 10% fetal bovine serum (Invitrogen/Gibco,
Carlsbad, CA, USA) (SDM-FBS) was added to each well.BMC Biology 2007, 5:10 http://www.biomedcentral.com/1741-7007/5/10
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After 72 hours of incubation at 25°C to allow for the turn-
over of the protein of interest, cells were collected for use
in the assays.
Tritiated-nutrient import assays
Cells were pelleted and resuspended to a density of about
1.5 million cells/mL in uptake assay buffer (UAB; 5.4 mM
KCl, 140 mM NaCl, 1.8 mM CaCl2, 0.8 mM MgSO4, 25
mM Hepes, 25 mM Tris), pH 7.5 [5] containing 10 μg/mL
bovine insulin (Sigma), and if used, inhibitors such as
LY294002 (Calbiochem, San Diego, CA, USA), AKT inhib-
itor (1L-6-Hydroxymethyl-chiro-inositol 2-(R)-2-O-
methyl-3-O-octadecylcarbonate; Calbiochem) or rapamy-
cin (LC Laboratories, Wobern MA, USA). After 30 minutes
equilibration time, 10 μCi/mL tritiated nutrient (15 3H-
amino acid mix; 16–92 Ci/mmol; TRK-440), 3H-arginine
(60 Ci/mmol; TRK698), or 2DG (Amersham Biosciences,
Piscataway NJ, USA) was added to each cell suspension.
The suspension was mixed by inversion. Assays were car-
ried out at room temperature over a period of 45–90 min-
utes. Duplicate aliquots of each cell suspension were
removed at 15–20 minute intervals for the duration of
each assay. Aliquots were collected and washed twice with
UAB to remove any extracellular tritiated nutrient. The
cells were then lysed with cell lysis buffer (100 mM Tris-
Cl, pH 8.0, 100 mM NaCl, 0.5% Triton X-100), vortexed,
and incubated in ice for at least 10 minutes to ensure com-
plete lysis. Lysates were transferred to scintillation vials
containing 3 mL scintillation buffer (EcoScint Original;
National Diagnostics, Atlanta GA, USA). The vials were
capped and mixed by inversion before the activity count
was obtained using a scintillation counter (Beckman
LS6500, Beckman-Coulter, Fullerton CA, USA). The activ-
ity (counts per minute; cpm) for each time point analyzed
was graphically illustrated using MS Excel for visual com-
parison of nutrient uptake kinetics of the control versus
experimental cell populations. If two separate popula-
tions were used for control and experimental groups, as
was the case with dsRNA-treated cells, the activity was nor-
malized to the number of cells/mL, cell volume/cell/mL,
or protein content. Experiments were carried out a mini-
mum of three times.
Determination of cell size
The mean cell size for each culture was determined using
a counter (Beckman Coulter Z2) set to count cells of size
5–20  μm. dsRNA-treated cultures were compared to
paired control dsGFP-treated cultures.
Determination of protein content
Protein content of a cell culture was determined using the
DC microplate protein assay (Biorad). Cell lysis was car-
ried out using the cell lysis buffer as described above.
Translation assay, S2 cells
In total, 2 mL of S2 cells in cultured medium was trans-
ferred to one well of a six-well dish, then 1 mL of fresh
SDM-FBS containing 15 μCi/mL tritiated amino acid mix
(Amersham Biosciences) was added to each well for a
final concentration of 5 μCi AA per mL culture. Following
3 hours of amino-acid incorporation at room tempera-
ture, 900 μL of suspended cells were split into three aliq-
uots, pelleted, and the media removed. The cells were
washed once with 200 μL UAB to remove excess non-
imported amino acids. The cells were lysed in 150 μL cell
lysis buffer as above then 12 μL resin (Strataclean; Strata-
gene) was added to each vial of cell lysate. The vials were
vortexed to disperse the resin and then left for at least 3
minutes to allow the resin to bind the protein. The resin
was pelleted by centrifugation and the remaining lysate
was decanted. The resin was washed once with 100 μL
UAB before being transferred to scintillation vials contain-
ing 3 mL scintillation liquid (EcoScint Original; National
Diagnostics). Using a scintillation counter (Beckman
LS6500) 10-minute scintillation counts were performed.
To validate the assay conditions, a resin-binding test was
performed. Radioactivity of resin-bound material (pro-
tein), as measured in cpm, was linear over the range of 5–
20 mL resin volume. The resin did not bind native amino
acids. Therefore, using a constant resin volume normal-
izes for protein content in this assay. Incorporation of 3H-
amino acids into resin-binding material (protein) was
also linear over a range of 25–350 minutes incorporation
time.
Translation assay, whole larvae
The S2 translation protocol above was modified for use
with whole larvae. Experimental larval genotypes were: hs-
Flp; Act>CD2>Gal4 UAS-GFP/UAS-Rheb (Figures 3A, B),
and hs-Flp; Act>CD2>Gal4 UAS-GFP/UAS-Dp110 or hs-Flp;
Act>CD2>Gal4 UAS-GFP/UAS-PTEN (Figure 3C). Control
genotypes were: hs-Flp; Act>CD2>Gal4 UAS-GFP in each
case. Triplicate sets of 10 larvae were inverted in Ringer's
solution and transferred to an eppendorf tube along with
100 μL Ringer's solution for the assay; 750 μL Ringer's
solution containing 15 μCi/mL tritiated amino acid mix
was added to each eppendorf tube. The larval carcasses
were rocked at room temperature for 1 hour, washed in
500 μL cold Ringer's solution, and lysed using mechanical
disruption of the larval carcasses in a total of 350 μL cell-
lysis buffer. Larval debris was pelleted, and 250 μL lysate
was transferred to a new vial. A quantity (15 μL) of resin
(Strataclean) resin was added to the lysate. Protein-bound
resin was then pelleted, washed with 150 μL Ringer's solu-
tion and transferred to 3 mL scintillation buffer, and 1-
minute counts were obtained (Beckman LS6500).BMC Biology 2007, 5:10 http://www.biomedcentral.com/1741-7007/5/10
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Northern blotting
A quantity (1 mL) of dsRNA-treated S2 cell culture (~2
million cells) was used for RNA extraction. Total RNA was
extracted using 1 mL of reagent (TRIzol; Invitrogen) using
standard procedures, followed by DNase I treatment for
15 minutes at 37°C and purification of the RNA (RNEasy
kit; Qiagen). RNA was stored at -70°C until it could be
used for Northern blot analysis. Equal volumes of total
RNA were loaded into a MOPS/formaldehyde gel for elec-
trophoretic separation. The RNA was blotted onto a posi-
tively charged nylon membrane (Roche) according to
standard procedures, and the transcript of interest was
detected using DIG-labeled antisense probes (DIG labe-
ling and detection, Roche).
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